ER negative

The combination of ΔDCEUS% and ΔEmax% demonstrated superior predictive ability for NAC response, with an area under the curve (AUC) of 0.906, outperforming ΔDCEUS% (AUC 0.871) or ΔEmax% (AUC 0.722) alone. CEUS combined with SWE shows promise for predicting pCR in invasive breast cancer undergoing NAC.

These data provide an expanded understanding of the molecular underpinnings of EMCG-including the first description of a SMARCA4 frameshift variant in this entity-and demonstrate that while gastrointestinal marker immunoexpression is relatively common among endometrial carcinomas, strictly defined EMCG remains rare (<1%). As awareness of this entity grows, pathologists should take care not to over-interpret gastrointestinal marker expression as stand-alone evidence of an EMCG diagnosis.

The pronounced effects in AA-derived ER- spheroids align with known disparities in tumor aggressiveness and suggest future NOHA clinical utility potential in racially diverse populations. Further in vivo validation is warranted to support and confirm such clinical translation.

Despite peritoneal carcinomatosis, the patient responded to cisplatin/gemcitabine chemotherapy and immunotherapy, demonstrating tumor shrinkage on follow-up imaging. This case highlights the diagnostic challenges of SRCC due to its nonspecific symptoms and potential histological overlap with other metastatic gastrointestinal tumors. Early recognition and a multidisciplinary approach are critical for improving patient outcomes.

Using different DTI parameters can enhance the accuracy of breast cancer characterization reducing unnecessary biopsies, provide valuable data to correlate with tumor grade, differentiate luminal from non-luminal lesions, thus providing insights into the aggressiveness of the tumor.

In patients with residual disease, pre- and post-NAC ER expression levels were found to be independent prognostic factors, but with no significant differences among ER-negative, ER-low positive, and ER-intermediate positive tumors. Our study indicates that ER-low positive BCs are similar to ER-negative BCs and that ER-intermediate positive BCs exhibit characteristics heterogeneous between ER-negative and ER-high positive BCs in terms of clinicopathological characteristics, chemo-responsiveness, and clinical outcomes.

These findings demonstrate markedly improved PRS accuracy for BC risk prediction in African-ancestry women. Using these PRS models for screening will help promote more equitable cancer prevention efforts.

P1, N=52, Recruiting, Immunolight, LLC | N=20 --> 52

Furthermore, high HIST1H4C expression before and after-treatment in our center or in database has a positively correlation with poor prognosis. HIST1H4C is the potential biomarker of neoadjuvant therapy and prognosis for breast cancer.

The ESGO-ESTRO-ESP 2025 classification re-assigns approximately one-tenth of patients, with a meaningful impact on adjuvant therapy. The rarity of estrogen receptor negativity limits its role in no-specific-molecular-profile stratification. Variation in lymph node involvement across molecular tumor categories highlights opportunities for individualized surgical staging.

P4, N=67, Not yet recruiting, The First Affiliated Hospital of Army Medical University; The First Affiliated Hospital of Army Medical University

P2, N=25, Not yet recruiting, The Third Bethune Hospital of Jilin University; The Third Bethune Hospital of Jilin University